LAVA Therapeutics N.V. Board of Directors

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Mr. Stephen Allen Hurly M.B.A., M.Sc.

Mr. Stephen Allen Hurly M.B.A., M.Sc.

CEO, President & Executive Director

Dr. Ton Adang Ph.D.

Dr. Ton Adang Ph.D.

Chief Development Officer

Ms. Amy Garabedian J.D.

Ms. Amy Garabedian J.D.

General Counsel & Corporate Secretary

Mr. Wouter van Hunnik

Mr. Wouter van Hunnik

VP & Head of Human Resources

Mr. Fred M. Powell CPA

Mr. Fred M. Powell CPA

Chief Financial Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.